Immunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
|
|
- Adelia Goodman
- 5 years ago
- Views:
Transcription
1 Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
2
3 Overall Survival for Metastatic Melanoma Proportion Alive Survival data from 42 phase II trials with over 2100 stage IV patients: 12-month OS: 25.5 %, Median OS: 6.2 months Time, Months Korn EL, et al. J Clin Oncol. 2008;26(4): Dummer R, et al. Ann Oncol. 2008;19 Suppl 2:ii Garbe C, et al. Eur J Cancer. 2010;46(2):
4 Melanoma Immunotherapy Spontaneous regression Vitiligo Halo-nevus
5 High-Dose IL-2 Response rate: 15%, with 5% complete response Grades 3-5 >50% and 2% death Atkins MB, et al. J Clin Oncol. 1999;17(7):
6 Boutros C, et al. Nat Rev Clin Oncol. 2016;13(8):
7 Anti-CTLA-4: Ipilimumab Pretreated Patients +/- gp100 HLA-A2 3 mg/kg Reinduction possible Naïve Patients + DTIC 10 mg/kg Maintenance possible Hodi FS, et al. N Engl J Med. 2010;363(8): Robert C, et al. N Engl J Med. 2011;364(26):
8 Anti-CTLA-4: Ipilimumab Plateau effect Hodi FS, et al. N Engl J Med. 2010;363(8): Robert C, et al. N Engl J Med. 2011;364(26):
9 Pembrolizumab Anti-PD-1 Two Phase I Trials ORR 30 and 40% Toxicity: 15% grade 3 Nivolumab Overall Survival, % year OS 49% Time, Months n at risk at Risk Total 2-year OS 48% 3-year OS 41% Months Ribas A, et al. JAMA. 2016;3.135(15): Hodi FS, et al. J Clin Oncol. 2014;32(5s): Abstract 9002.
10 Phase III Nivolumab vs Chemotherapy Phase III Pembrolizumab vs Ipilimumab 1-yr OS 73% (n = 210) (n = 208) 1-yr OS 42% Treatment Arm Median (95% CI), mo Rate at 12 mo HR (95% CI) P Pembrolizumab Q2W NR (NR-NR) 74.1% 0.63 ( ) Pembrolizumab Q3W NR (NR-NR) 68.4% 0.69 ( ) < < Ipilimumab NR (12.7-NR) 58.2% Follow-up since randomization: months Decreased risk of death by 58% compared to chemotherapy, and by 31% to 37% compared with ipilimumab Robert C, et al. N Engl J Med. 2015;372(4): Robert C, et al. N Engl J Med. 2015;372(26):
11 Early Effect of Checkpoint Inhibitors
12 Adjuvant Treatment With Ipilimumab Eggermont AM, et al. N Engl J Med. 2016;375(19):
13 Adjuvant Treatment With Nivolumab vs Ipilimumab: CheckMate 238 Enrollment period: March 30, 2015 to November 30, 2015 Patients with high-risk, completely resected stage IIIB/IIIC or stage IV melanoma 1:1 n = 453 n = 453 Stratified by: 1) Disease stage: IIIB/C vs IV M1a-M1b vs IV M1c 2) PD-L1 status at a 5% cutoff in tumor cells NIVO 3 mg/kg IV q2w and IPI placebo IV q3w for 4 doses then q12w from week 24 IPI 10 mg/kg IV q3w for 4 doses then q12w from week 24 and NIVO placebo IV q2w Follow-up Maximum treatment duration of 1 year Weber J, et al. N Engl J Med. 2017;377(19): Weber J, et al. Ann Oncol. 2017;28(Suppl 5): Abstract LBA8_PR.
14 Nivolumab Is Superior to Ipilimumab in the Adjuvant Setting NIVO IPI Events/patients 154/ / Median (95% CI) NR NR (16.6, NR) RFS, % % 61% 66% 53% HR (97.56% CI) 0.65 (0.51, 0.83) Log-rank P value < Number of patients at risk NIVO IPI NIVO IPI Months Weber J, et al. N Engl J Med. 2017;377(19): Weber J, et al. Ann Oncol. 2017;28(Suppl 5): Abstract LBA8_PR.
15 KEYNOTE-054: Adjuvant Pembrolizumab in High-Risk Stage III Melanoma Patients with high-risk, completely resected stage III melanoma R A N D O M I Z E Pembro 200 mg IV on day 1 of each 21-day cycle Placebo IV on day 1 of each 21-day cycle Follow-up Maximum treatment duration of 1 year Primary Endpoint: Recurrence-free survival (RFS) for all participants, RFS for participants with PD-L1 positive tumor expression Secondary Endpoints: Distant metastases-free survival (DMFS) for all participants, DMFS for participants with PD-L1 positive tumor expression, OS in all participants, OS in participants with PD-L1 positive tumor expression Results expected spring 2018 National Institutes of Health. Accessed November 9, 2017.
16 CheckMate 067: Combination of Immunotherapies Progression-Free Survival Overall Survival Wolchok JD, et al. N Engl J Med. 2017;377(14):
17 First-Line Therapy: Overall Survival Mean survival curves created by weighted averaging of digitized Kaplan-Meier survival curves of metastatic melanoma patients treated in selected clinical trials. Ugurel S, et al. Eur J Cancer. 2016;53:
18 Unpublished data. Longer Follow-Up
19 Unpublished data. Longer Follow-Up
20 New Toxicity Profile
21 Which of the following adverse events would you NOT consider to be immune related in a patient receiving checkpoint inhibitor therapy for the treatment of melanoma? 1. Pneumonitis 2. Rash 3. Hypertension 4. Colitis 5. Hepatotoxicity
22 More Organs or Tissues Can Be Involved Michot JM, et al. Eur J Cancer. 2016;54:
23 But: High Toxicity of the Combination Grade 3/5 AE % Discontinuation for AE % Ipilimumab 3 mg/kg Nivolumab Pembrolizumab Ipilimumab + nivolumab Atkinson V, et al. Presented at: 9 th World Congress of Melanoma. October 18-21, Brisbane, Australia. 2. Weber J, et al. N Engl J Med. 2017;377(19): Ribas A, et al. JAMA. 2016;315(15): Wolchok JD, et al. N Engl J Med. 2017;377(14):
24 Immunotherapy Adverse Events Boutros C, et al. Nat Rev Clin Oncol. 2016;13(8):
25 Bompaire F, et al. Invest New Drugs. 2012;30(6):
26 Vitiligo With Anti-PD1 or Anti-PDL1
27 Vitiligo and Clinical Response to Pembrolizumab Patient CR PR SD PD P* Vitiligo (n = 17) 3 (18) 9 (53) 3 (18) 2 (12).002 No vitiligo (n = 50) 4 (8) 10 (20) 1 (2) 35 (70) Total (N = 67) 7 (10) 19 (28) 4 (6) 36 (54) *Complete/partial response versus stable/progressive disease/progression in patients with and without vitiligo, exact Fisher test Hua C, et al. JAMA Dermatol. 2016;152(1):45-51.
28 New Evaluation Criteria
29 New Types of Responses Wolchock JD, et al. Clin Cancer Res. 2009;15(23): Immune-Related Response Criteria
30 Baseline 12 weeks 24 weeks 52 weeks
31 New Reasons to Stop Treatment
32 Pembrolizumab Phase I: KEYNOTE-001 : Median Follow-Up 43 Months for 655 Patients On treatment: 16% Consent withdrawal 5% Discontinue for physician decision 11% Discontinued for PD: 42% Discontinued for AEs: 25% Range of follow-up: months. Analysis cutoff date: September 1, Robert C, et al. Presented at: 13 th Congress of the European Association of Dermato Oncology; May 3-6, 2017; Athens, Greece.
33 Complete Responders: Disposition Median follow-up: 43 months 92 (88%) remained in CR a 105 (16%) patients had CR per irrc by investigator review 14 (13%) remained on pembrolizumab 24 (23%) discontinued for AEs (n = 12), PD (n = 2), or other reason (n = 10) 67 (64%) stopped pembrolizumab for observation a Patient was alive and without disease progression. Analysis cutoff date: September 1, Robert C, et al. Presented at: 13 th Congress of the European Association of Dermato Oncology; May 3-6, 2017; Athens, Greece.
34 Complete Responders Who Stopped Pembrolizumab for Observation (N = 67) Median time to CR: 13 mo ( 3-36 mo) 61 (91%) responses were maintained Median response duration: NR (6+ to 56+ mo) Time to PD or last assessment Last dose CR PR PD Time to death Time, months Total bar length represents the time to the last scan. Analysis cutoff date: September 1, Robert C, et al. Presented at: 13 th Congress of the European Association of Dermato Oncology; May 3-6, 2017; Athens, Greece.
35 In KEYNOTE-006, what is the estimated PFS at follow-up in patients who completed protocolspecified time on treatment? 1. 61% 2. 71% 3. 81% 4. 91%
36 KEYNOTE-006 (NCT ) Patients Unresectable, stage III or IV melanoma 1 previous therapy, excluding anti CTLA-4, PD-1, or PD-L1 agents Known BRAF mutation status a ECOG PS 0-1 No active brain metastases No serious autoimmune disease R 1:1:1 Pembrolizumab 10 mg/kg intravenous q2w for 2 years Pembrolizumab 10 mg/kg intravenous q3w for 2 years Ipilimumab 3 mg/kg intravenous q3w 4 doses Stratification Factors ECOG PS (0 vs 1) Line of therapy (first vs second) PD-L1 status b (positive vs negative) Primary endpoints: PFS and OS Secondary endpoints: ORR, duration of response, safety Robert C, et al. J Clin Oncol. 2017;35(suppl): Abstract a Prior anti-braf targeted therapy was not required for patients with normal LDH levels and no clinically significant tumor-related symptoms or evidence of rapidly progressing disease. b Defined as 1% staining in tumor and adjacent immune cells as assessed by IHC (22C3 antibody).
37 KEYNOTE-006: Patients Who Completed Protocol-Specified Time on Pembrolizumab (Median Follow-Up, 9.7 mo) 556 patients received pembrolizumab 104 (19%) completed pembrolizumab 24 (23%) CR 68 (65%) PR 12 (12%) SD 23 ongoing responses 1 PD b 1 received second course of pembrolizumab 64 ongoing responses 4 PD b 3 received second course of pembrolizumab 10 ongoing SD 2 deaths b,c Robert C, et al. J Clin Oncol. 2017;35(suppl): Abstract a Includes patients completing 21.6 months of treatment. b From end of pembrolizumab treatment. c Both deaths were a result of PD. Data cutoff date: Nov 3, 2016.
38 PFS (irrc, Investigator) From Last Pembrolizumab Dose in Patients Who Completed Protocol-Specified Time on Treatment (n = 104) Progression-Free Survival, % Patients Who Completed Protocol-Specified Time on Pembrolizumab, n Estimated PFS, % (95% CI) 102 (98%) patients were alive after a median of 9.7 months after completing pembrolizumab treatment Median PFS (80-96) NR No. at risk Time, Months Robert C, et al. J Clin Oncol. 2017;35(suppl): Abstract Data cutoff date: Nov 3, 2016.
39 Ipilimumab + Nivolumab: Pooled Data From CheckMate 067 and 69 Schadendorf D, et al. J Clin Oncol Aug 25. [Epub ahead of print].
40 Ipilimumab + Nivolumab: Pooled Data From CheckMate 067 and 09 PFS and OS not significantly different between the patients who discontinued for AE during the induction period and those who did not discontinue Schadendorf D, et al. J Clin Oncol Aug 25. [Epub ahead of print].
41 Ipilimumab + Nivolumab: Pooled Data From CheckMate 067 and 09 Patients who discontinued treatment because of adverse events during the induction phase of treatment. Schadendorf D, et al. J Clin Oncol Aug 25. [Epub ahead of print].
42 To Improve Benefit/Risk Ratio Recent Results on Combinations Combination targeted therapy + anti PD1/PDL-1 Cobimetinib/vemurafenib/atezolizumab Dabrafenib/trametinib/pembrolizumab Combination of immunotherapies Pembrolizumab/ipilimumab 1 mg/kg Pembrolizumab/TVEC Pembrolizumab/anti-IDO epacadostat In anti-pd1 refractory patients Nivolumab/anti-Lag3 relatlimab
43 Early Combination Studies KEYNOTE Pembro + Dabra + Trame GP Cobi + Vemu + Atezo KEYNOTE Pembro + Epacadostat KEYNOTE Pembro + Ipi1 mg Pembro + TVEC 5 Nivo+ Relatlimab 6 N High LDH (%) NR M1C (%) * 47.5 ORR (%) CR (%) ** 1.6 Grade 3/5 AE (%) Median FU (months) * But 44% III or M1a; ** including injected lesions 1. Ribas A, et al. Ann Oncol. 2017;28(Suppl 6): Abstract 1216O. 2. Hwu P, et al. Ann Oncol. 2016;27(Suppl 6): Abstract 1109PD. 3. Hamid O, et al. Ann Oncol. 2017;28(Suppl 6): Abstract 1214O. 4. Long GV, et al. Lancet Oncol. 2017;18(9): Ribas A, et al. Cell. 2017;170(6): Ascierto PA, et al. Ann Oncol. 2017;28(Suppl 6): Abstract LBA18.
44 New Biomarkers
45 PD-L1 High Expression Associated With Clinical Response to Anti-PD1 100 ORR, RECIST v1.1 Correlation between PD-L1 expression and ORR (P<.0001) ORR, % (95% CI) PD-L1 Negative 0% Staining APS = 0 PD-L1 Positive 1-10% Staining APS = 2 APS, Allred proportion score. Analysis cut-off date: October 18, PD-L1 Positive 10-33% Staining APS = 3 PD-L1 Positive % Staining APS = APS 0 n = 28 APS 1 n = 24 Negative Daud A. Presented at: 2015 American Society of Clinical Oncology Annual Meeting: Clinical Science Symposium Intersection of the Mutanome and the Immunome; May 29-June 2, 2015; Chicago, Illinois. APS 2 n = 72 APS 3 n = 54 APS 4 n = 32 Positive APS 5 n = 34
46 Which of the following is NOT a difference between PD-L1 testing platforms? 1. PD-L1 expression level cutoff 2. Use of immune cells for expression testing 3. Use of tumor cells for expression testing 4. Antibody used for testing
47 Heterogeneity of PD-L1 IHC Assays Clone Species Assay Developer Treatment Drug Target 22C3 Mouse Dako Pembrolizumab PD Rabbit Dako Nivolumab PD-1 SP142 Rabbit Ventana Atezolizumab PD-L1 Relevant Cutoff From Clinical Trials TC 5% (melanoma) Any intensity TC 1% Any intensity TC 50%/5%/1% Moderate and strong intensity IC 10%/5%/1% SP263 Rabbit Ventana Durvalumab PD-L1 TC 25% Any intensity 04/12/2017 TC, tumor cells; IC: immune cells Courtesy Julien Adam, Gustave Roussy Other antibodies - 5H1 (Lieping Chen), mouse mab - E1L3N (Cell signaling technology), rabbit mab
48 Courtesy Julien Adam, Gustave Roussy
49 Among Several Markers, CD8+ Was the Most Predictive for Response to Pembrolizumab Tumeh PC, et al. Nature. 2014;515(7528):
50 Role of the Gut Microbiota? Baseline microbiota type is linked to the risk of colitis and response to immunotherapy Chaput N, et al. Ann Oncol. 2017;28(6):
51 Mutational Load and Neoantigens Number of nonsynonymous mutations Generation of neoantigens Anti-CTLA-4 in Melanoma Snyder A, et al. N Engl J Med. 2014;371(23): Rizvi NA, et al. Science. 2015;348(6230): Anti-PD-1 in NSCLC
52 Mutational Load and Neoantigens Alexandrov LB, et al. Nature. 2013;500(7463): Schumacher TN, et al. Science. 2015;348(6230):69-74.
53 New Mechanisms of Resistance
54 Genetic Resistances to Immunotherapies Mutation-derived modification of the INF-γ signaling pathway or loss of Cl I expression Zaretsky JM, et al. N Engl J Med. 2016;375(9): Gao J, et al. Cell. 2016;167(2):
55 Many Avenues Are Explored to Overcome the Resistance + radiotherapy + other IT 41BB OX-40 CD40 GITR ICOS IDO + other checkpoint-i TIM 3; LAG 3 + macrophage-i CSFR1 + chemo + local tt Ipi Oncol virus TLR agonist + cancer vaccines + Adopt C T + targeted therapies BRAF, MEK + epigenetic modifiers HDAC + NK activation
56 Genetic background: MHC DNA-repair system Immune background Tumor specific: Mutations, neoantigens DNA-repair capacity Immune targets: PD1, PDL-1, Lag-3 Metabolism: LDH, oxphos, glycolysis Translation initiation Microbiome Gut Skin Immune landscape : Immunoscore: CTL, repertoire, Treg, B cells, Tfh, MDSC, Immune biomarkers: PD1, PDL-1, PLA Lag-3,
57 This is the revolution Conclusion Real hope to cure some patients For some others, nothing has changed (high LDH, multiple brain metastases) We have to continue Clinical trials with translational research Combination, or sequences of drugs Biomarker identification
58 Clinical and Research Teams
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationImmune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes
Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Geoffrey T. Gibney, MD Associate Professor Co-leader, Melanoma Disease Group Lombardi Comprehensive Cancer Center
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationReview of immunotherapy in melanoma
Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationMELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone
MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationWHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example
WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example YIDOU ZHANG Health Economics and Payer Analytics Director Oncology Payer Evidence and Pricing, AstraZeneca
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced Melanoma
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationKombination von Checkpointinhibitoren beim malignen Melanom
Kombination von Checkpointinhibitoren beim malignen Melanom Dirk Jäger Medizinische Onkologie Nationales Centrum für Tumorerkrankungen Universitätsklinikum Heidelberg Ipilimumab beim metastasierten Melanom
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationIMMUNOTARGET THERAPY: ASPETTI GENERALI
IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationMelanoma: What else beyond Checkpoint Inhibitor pathway?
Melanoma: What else beyond Checkpoint Inhibitor pathway? Jose Lutzky MD, FACP Director, Mount Sinai Melanoma Program Miami Beach, Florida Clinical Associate Professor, Wertheim School of Medicine, FIU,
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationImmune checkpoint inhibition in melanoma. John Haanen
Immune checkpoint inhibition in melanoma John Haanen ESMO Preceptorship Singapore 217 Immune Checkpoint inhibitors Immune checkpoints play an important role in immune tolerance Cancer hijacks many of these
More informationNew Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy
New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology
More informationA Case Study: Ipilimumab in Pre-treated Metastatic Melanoma
A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma Tai-Tsang Chen, PhD Global Biometric Sciences, Bristol-Myers Squibb EFSPI Statistical Meeting on Evidence Synthesis Brussels, Belgium November
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationImmune checkpoint inhibition in melanoma
Immune checkpoint inhibition in melanoma John Haanen ESMO Preceptorship Zürich 217 Disclosures I have provided consultation, attended advisory boards, and/or provided lectures for: Pfizer, MSD, BMS, IPSEN,
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationNuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.
Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Andrea Anichini Human Tumors Immunobiology Unit Dept. of Experimental Oncology and Molecular Medicine Immune checkpoint
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationCancer Immunotherapy in the Modern Era. David R. Spigel, MD Sarah Cannon Research Institute Nashville, Tennessee
Cancer Immunotherapy in the Modern Era David R. Spigel, MD Sarah Cannon Research Institute Nashville, Tennessee Key Events in the History of Cancer Immunotherapy 1890 First cancer vaccine developed (Coley)
More information